Antithrombotic drugs

PreclinicalSmall molecule

Antithrombotic drugs is one of 69 small molecule programs targeting Acute Coronary Syndrome. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Coronary SyndromeActive, not recruiting

Intracranial HemorrhageActive, not recruiting

Ischemic StrokeActive, not recruiting

Acute Coronary SyndromePreclinical

Active, not recruiting

Intracranial HemorrhagePreclinical

Active, not recruiting

Ischemic StrokePreclinical

Active, not recruiting

Competition

Competitive Landscape

430 competitors in Ischemic Stroke

#DrugCompanyPhaseTrials

Proamatine

Takeda

Preclinical

2 2

Repatha

Amgen

Preclinical

2 3

Levaquin

WWim Janssens

Preclinical

3 4

Tylenol

KKenvue Brands

Preclinical

1 5

Xylocaine

CCitius Pharmaceuticals, Inc.

Preclinical

1 6

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

1 7

Statins

Sanofi

Preclinical

1 8

Urokinase

Mmedac GmbH

Preclinical

3 9

Drug Therapy

MMassachusetts General Hospital

Preclinical

1 10

Ginkgo Biloba Extract

NNational Center for Complementary and Integrative Health (NCCIH)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Recruiting

Ischemic Stroke

NCT05032053

Q4 2027

Not yet recruiting

Antithrombotic

NCT07338071

Clinical

Trials by Indication[1]

Intracranial Hemorrhage1 trial

Risk of Intracranial Hemorrhage in Users of Oral Antithrombotic Drugs

Completed·SSt. Olavs Hospital··NCT02481011·22,111 enrolled

Antithrombotic1 trial

Antithrombotic Therapy at the End of Life: The PEACE Study

Not yet recruiting·FFondazione Policlinico Universitario Agostino Gemelli IRCCS··NCT07338071·410 enrolled

Age1 trial

Management of TA in VaS-Patients and HT

Unknown status·XXijing Hospital··NCT04726007·1,500 enrolled

Acute Coronary Syndrome1 trial

Treatment and Outcomes of Atrial Fibrillation and Acute Coronary Syndrome in Sweden

Completed· Bayer logo

Bayer··NCT03311139·14,226 enrolled

Ischemic stroke1 trial

Antithrombotic Drug Use in Patients With Ischemic Stroke and Microbleeds

Recruiting·XXijing Hospital··NCT05032053·3,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Antithrombotic drugs. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Antithrombotic drugs compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Antithrombotic drugs. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bayer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Bayer

Antithrombotic drugs

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Trials by Indication[1]

Intracranial Hemorrhage1 trial

Antithrombotic1 trial

Age1 trial

Acute Coronary Syndrome1 trial

Ischemic stroke1 trial

References

Drug Info

Quick Facts

Related News